BrainsWay Reports Strong 2025 Financials, Expands Deep TMS Indications, and Bolsters Strategic Investments Amid IP Challenge

summarizeSummary

BrainsWay reported strong 2025 financial growth, expanded its Deep TMS FDA clearances, and made strategic investments in at-home neuromodulation and MSOs, while facing new IP infringement allegations and patent expirations.

check_boxKey Events

• Strong 2025 Financial Performance

  Reported a 27.3% increase in revenues to $52.2 million and a 161% increase in net income to $7.6 million for the year ended December 31, 2025.

• Expanded FDA Clearances for Deep TMS

  Received FDA clearance in November 2025 for Deep TMS to treat adolescent (ages 15-21) Major Depressive Disorder (MDD) as an adjunct therapy, and in September 2025 for an accelerated treatment protocol for MDD.

• Strategic Investment in At-Home Neuromodulation

  Entered into an investment agreement with Neurolief in August 2025, which subsequently received FDA Premarket Approval in January 2026 for its Proliv™Rx system, the first FDA-approved at-home neuromodulation device for MDD.

• Investments in Management Service Organizations (MSOs)

  Made multiple minority investments in MSOs totaling approximately $10.8 million in 2025 and early 2026 (Stella MSO, Axis Management Company, Tangient ATX Inc., BrainStim Health Inc.) to expand market access for mental health therapies.

auto_awesomeAnalysis

BrainsWay Ltd. delivered robust financial results in 2025, with significant revenue and net income growth, driven by increased sales and leases of its Deep TMS systems. The company expanded its market reach through new FDA clearances for adolescent and accelerated MDD treatment protocols, and strategically invested in Neurolief, gaining access to an FDA-approved at-home neuromodulation device for MDD. Additionally, BrainsWay made several minority investments in Management Service Organizations (MSOs) to enhance market penetration. However, these positive developments are tempered by the expiration of key Deep TMS patents and a new IP infringement claim from Magnus Medical Inc. regarding its accelerated protocol, which could pose competitive and legal challenges. Investors should monitor the outcome of the IP dispute and the company's ability to leverage its expanded product portfolio and strategic partnerships to mitigate patent expiration risks and sustain growth.